Trial · NCT07879807
Post-Stroke Apraxia, Motor Function, Balance, and Gait
NCT07879807, Recruiting, Izmir City Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-Stroke Apraxia, Motor Function, Balance, and Gait. Trials, record NCT07879807. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879807
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-Stroke Apraxia, Motor Function, Balance, and Gait
- NCT number
- NCT07879807
- Status
- Recruiting
- Enrollment
- 54 participants, estimated
- Lead sponsor
- Izmir City Hospital
- Conditions
- Stroke, Ideomotor Apraxia, Hemiplegia
- Interventions
- Standardized clinical assessment
- First posted
- 2026-10-19
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Motor Functional Independence Measure (Motor FIM) Score | At enrollment, during a single assessment session | The Motor FIM comprises 13 items assessing self-care, sphincter control, transfers, and locomotion. Scores range from 13 to 91, with higher scores indicating greater functional independence. Motor FIM scores will be compared between participants with and without ideomotor apraxia (defined by the Test for Upper Limb Apraxia \[TULIA\] cut-off), and their association with the TULIA total score will be examined. |
| Secondary | Fugl-Meyer Assessment Upper Extremity Motor Score | At enrollment, during a single assessment session | Upper limb motor impairment will be assessed using the upper extremity motor section of the Fugl-Meyer Assessment. Scores range from 0 to 66, with higher scores indicating better motor function. Its association with the TULIA total score will be examined. |
| Secondary | Functional Ambulation Categories Score | At enrollment, during a single assessment session | Walking independence will be assessed using the Functional Ambulation Categories, scored from 0 to 5. Higher scores indicate greater walking independence and less need for assistance from another person. Its association with the TULIA total score will be examined. |
| Secondary | Comfortable Walking Speed on the 10-Meter Walk Test | At enrollment, during a single assessment session | Comfortable walking speed will be assessed using the 10-Meter Walk Test and expressed in meters per second. Higher values indicate faster walking speed. Its association with the TULIA total score will be examined. |
| Secondary | Total Functional Independence Measure Score | At enrollment, during a single assessment session | Overall functional independence will be assessed using the 18-item Functional Independence Measure, covering motor and cognitive domains. Total scores range from 18 to 126, with higher scores indicating greater independence. Its association with the TULIA total score will be examined. |
| Secondary | Berg Balance Scale Score | At enrollment, during a single assessment session | Balance will be assessed using the Berg Balance Scale, comprising 14 items scored from 0 to 4. Total scores range from 0 to 56, with higher scores indicating better balance. Its association with the TULIA total score will be examined. |
| Other | Test for Upper Limb Apraxia (TULIA) Total Score | At enrollment, during a single assessment session. | Ideomotor apraxia will be assessed through imitation and pantomime of meaningless, intransitive, and transitive gestures. Scores range from 0 to 240, with lower scores indicating more severe apraxia. Participants scoring below the established cut-off will be classified as having ideomotor apraxia. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 19614961 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879807
GET https://conductscience.org/api/trials/v1/NCT07879807/registered